The guidance provides recommendations to sponsors holding Investigational New Drugs, New Drug Applications, and Biologics License Applicatons on what pharmacogenomic data to submit to the Agency during the drug development process, the format of submissions, and how the data will be used in regulatory decisionmaking.
US Code:
21 USC 312
Name of Law: Investigational New Drug Apllication
Based on our experience with the submission of voluntary genomic data submissions under this guidance over the past few years, the number of annual responses has been reduced from 7 to 4 because of reduced submissions. There are no other changes or adjustments.
On behalf of this Federal agency, I certify that the collection of information encompassed by this request complies with 5 CFR 1320.9 and the related provisions of 5 CFR 1320.8(b)(3).
The following is a summary of the topics, regarding the proposed collection of information, that the certification covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control number;
If you are unable to certify compliance with any of these provisions, identify the item by leaving the box unchecked and explain the reason in the Supporting Statement.